Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-03-18
2008-03-04
Swope, Sheridan (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069700, C530S389100, C530S388260
Reexamination Certificate
active
07339031
ABSTRACT:
The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
REFERENCES:
patent: 6680296 (2004-01-01), Stirpe et al.
patent: WO 98/52976 (1998-11-01), None
patent: WO 98/58678 (1998-12-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 02/069232 (2002-09-01), None
patent: WO 02/079415 (2002-10-01), None
patent: WO 03/103715 (2003-12-01), None
Galye et al, Identification of regions in interleukin-1 alpha important for activity. J Biol Chem. Oct. 15, 1993;268(29):22105-11.
Whisstock et al, Prediction of protein function from protein sequence and structure. Q Rev Biophys. Aug. 2003;36(3):307-40. Review.
di Paolo et al, A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res. Jul. 2003;9(7):2837-48. Erratum in: Clin Cancer Res. Apr. 1, 2004;10(7):2579.
Den Hartog, M T et al. (2002), Cloning and expression of cDNA coding for bouganin,Eur J Biochem,269(6):1172-1179.
Baker Matthew
Bosc Denis Georges
Carr Francis J.
Cizeau Jeannick
Entwistle Joycelyn
Dann Dorfman Herrell & Skillman P.C.
Merck Patent GmbH
Netter Robert C.
Swope Sheridan
LandOfFree
Modified bouganin proteins, cytotoxins and methods and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified bouganin proteins, cytotoxins and methods and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified bouganin proteins, cytotoxins and methods and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3964469